SAN

84.64

-0.96%↓

MRK1

119.5

-0.29%↓

SHL.DE

42.55

+0.59%↑

ARGX

791.4

-0.53%↓

PHIA

22.7

-5.73%↓

SAN

84.64

-0.96%↓

MRK1

119.5

-0.29%↓

SHL.DE

42.55

+0.59%↑

ARGX

791.4

-0.53%↓

PHIA

22.7

-5.73%↓

SAN

84.64

-0.96%↓

MRK1

119.5

-0.29%↓

SHL.DE

42.55

+0.59%↑

ARGX

791.4

-0.53%↓

PHIA

22.7

-5.73%↓

SAN

84.64

-0.96%↓

MRK1

119.5

-0.29%↓

SHL.DE

42.55

+0.59%↑

ARGX

791.4

-0.53%↓

PHIA

22.7

-5.73%↓

SAN

84.64

-0.96%↓

MRK1

119.5

-0.29%↓

SHL.DE

42.55

+0.59%↑

ARGX

791.4

-0.53%↓

PHIA

22.7

-5.73%↓

Home・Aandelen Lijst・Pharming Group NV

P
Pharming Group NV

Gesloten

1.418 4.19

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

1.357

Max

1.422

Belangrijke statistieken
By Trading Economics
Inkomsten	2.9M 7.5M
Verkoop	4.1M 97M
EPS	0.009
Winstmarge	7.758
Werknemers	404

Marktinformatie
By TradingEconomics
Marktkapitalisatie	-51M 946M
Vorige openingsprijs	-2.77
Vorige sluitingsprijs	1.418

Pharming Group NV Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

3 dec 2025, 23:21 UTC

Winsten

Acquisities, Fusies, Overnames

EQB to Buy Loblaw Unit PC Financial for About $573.5 Million -- Update

3 dec 2025, 23:14 UTC

Acquisities, Fusies, Overnames

EQB to Buy PC Financial From Loblaw for About $573.5 Million

3 dec 2025, 22:01 UTC

Belangrijke Marktbewegers

Costco Wholesale Reports Higher Monthly Sales

3 dec 2025, 21:38 UTC

Winsten

Salesforce Raises Revenue Forecast as Agentforce Sales Top $500 Million

3 dec 2025, 23:59 UTC

Marktinformatie

Australian Coal Prices Seen Having Recovered Well -- Market Talk

3 dec 2025, 23:49 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

3 dec 2025, 23:49 UTC

Marktinformatie

HSBC Chair Appointment Unlikely to Have Material Operational Impact -- Market Talk

3 dec 2025, 23:49 UTC

Marktinformatie

Nikkei May Decline Amid Caution Over U.S. Labor Market -- Market Talk

3 dec 2025, 23:13 UTC

Marktinformatie

Australian Treasurer Says Economy Not On Drip of Govt Spending -- Market Talk

3 dec 2025, 23:10 UTC

Winsten

Salesforce Raises Forecast as Agentforce Sales Top $500M -- Update

3 dec 2025, 23:08 UTC

Marktinformatie

Goodman's New Bull Sees Profit Upgrade on Cards -- Market Talk

3 dec 2025, 23:06 UTC

Acquisities, Fusies, Overnames

EQB to Buy Loblaw Unit PC Financial for About $573.5M -- Update

3 dec 2025, 22:59 UTC

Acquisities, Fusies, Overnames

EQB to Buy PC Financial From Loblaw for About $573.5M

3 dec 2025, 22:45 UTC

Marktinformatie

WiseTech Investor Day Increases Bull's Confidence -- Market Talk

3 dec 2025, 22:20 UTC

Winsten

Salesforce CEO: 9,500 of 18,500 Total Closed Agentforce Deals Are Paid

3 dec 2025, 22:19 UTC

Winsten

Salesforce CEO: Six Out of 10 Biggest Deals in 3Q Came from Agentforce

3 dec 2025, 22:17 UTC

Winsten

Salesforce Working to Add Voice to Agentforce, CEO Says

3 dec 2025, 22:16 UTC

Winsten

Salesforce CEO: Williams-Sonoma's Agentforce Makes Up 60% of Customer Chats

3 dec 2025, 22:15 UTC

Winsten

Salesforce CEO: Agentforce ARR Was $540M in 3Q

3 dec 2025, 22:10 UTC

Acquisities, Fusies, Overnames

EQB: Will Enter Into a Long-Term Strategic Relationship With Loblaw >EQB.T

3 dec 2025, 22:09 UTC

Acquisities, Fusies, Overnames

EQB: Agreed to Acquire PC Fincl From Loblaw >EQB.T

3 dec 2025, 21:50 UTC

Marktinformatie

Auto & Transport Roundup: Market Talk

3 dec 2025, 21:50 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

3 dec 2025, 21:49 UTC

Winsten

Salesforce Reports Mounting Profits. The Stock Is Rising. -- Barrons.com

3 dec 2025, 21:23 UTC

Winsten

Salesforce Raises Revenue Forecast as Agentforce Sales Top $500M

3 dec 2025, 21:19 UTC

Winsten

Salesforce Reports Mounting Profits. The Stock Is Rising. -- Barrons.com

3 dec 2025, 21:06 UTC

Winsten

Salesforce Reports Mixed Earnings. The Stock Is Rising. -- Barrons.com

3 dec 2025, 21:04 UTC

Winsten

Salesforce Sees Profitable Growth Framework Target of 50 by FY30 >CRM

3 dec 2025, 21:04 UTC

Winsten

Salesforce Targets $60 B Plus Organic Rev by FY30 >CRM

3 dec 2025, 21:03 UTC

Winsten

Salesforce Raises FY26 Oper Cash Flow Growth Guidance to 13% to 14% Y/Y >CRM

Peer Vergelijking

Prijswijziging

Pharming Group NV Prognose

Beoordelingsconsensus

By TipRanks

0 ratings

Buy

Hold

Sell

Gebaseerd op 0 analisten die aandelenratings hebben gegeven aan Pharming Group NV - Dist in de afgelopen 3 maanden.

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Pharming Group NV

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K" inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands.